Innovations in the diagnosis and management of uveitis: promising research to address unmet patient needs.

Uveitis, or inflammation of the uveal tissues (iris, ciliary body and the choroid), and its contiguous structures, can lead to severe visual impairment and is among the leading causes of vision impairment worldwide (1). In clinical practice, specialists in uveitis and ocular immunology are called upon to manage a range of uveitis syndromes—infectious disease, noninfectious autoimmune conditions, and masquerade syndromes such as lymphoma. Moreover, ophthalmologists of all subspecialties (i.e., medical and surgical retina, corneal surgeons, orbital/oculoplastic surgeons, and comprehensive ophthalmologists) are called upon to manage uveitis syndromes, emphasizing clear importance to understanding common uveitis syndromes, diagnostic workups, and the state-of-the-art in uveitis and ocular inflammation care. Recent advances uveitis disease nomenclature for classification, clinical trials, and laboratory testing involving “omics” insight into disease as well as opportunities for understanding new etiologies of uveitis and therapeutic targets. In this special series the Annals Eye Science entitled “Innovations in the Diagnosis and Management of Uveitis”, we highlight recent diagnosis treatment of uveitis, including both infectious and noninfectious entities, molecular diagnostic techniques, key relationships between gut microbiome and the pathogenesis of uveitis In addition, we also synthesize the literature related to multimodality diagnostic imaging and novel therapies for adults and children with complex inflammatory eye disease. Our recent understanding of uveitis of melanocyte including and antigens in with and which bears similarities in T-cell targeting These interplay between T-cells and melanocytic antigen observed in